Research
Size:
Share:

LADDER - Sponsored by Roche/Genenthech

Active Study | Duration: 38 weeks


LADDER is a multicenter, randomized, active-treatment controlled Phase II clinical trial for the treatment of wet AMD that evaluates the safety and efficacy of the Ranibizumab Port Delivery System (RPDS). RPDS is a surgically implanted intraocular device that delivers the drug Ranibizumab, brand name Lucentis┬«, to the retina. As opposed to the current method of monthly intravitreal injections for patients with chronic or recurrent wet AMD, RPDS offers a sustained and long-term medication delivery system that decreases the number of eye injections while potentially improving treatment outcome. This study is for patients who have been newly diagnosed with wet AMD within nine months prior to enrollment.    

Patients are treated and followed for 38 weeks. 

Enrollment is now closed for this study. Trials are in progress under the direction of Clinical Research Coordinator Maya Talatory (301-986-1477/mtalatory@rgw.com).

Return to Age-Related Macular Degeneration